School of Medicine


Showing 521-540 of 640 Results

  • Kiarash Shamardani

    Kiarash Shamardani

    Ph.D. Student in Cancer Biology, admitted Summer 2019

    Current Research and Scholarly InterestsInterested in a systems neuroscience approach to understanding the interaction of tumor cells and their microenvironment in brain cancer. I am studying the neuron-glioma interactions at the circuit level to discern how patterns of activity within a neuron-glioma network influences the behavior of the cancer as a whole.

  • Andrew A. Shelton, MD, FACS, FACRS

    Andrew A. Shelton, MD, FACS, FACRS

    Clinical Professor, Surgery - General Surgery

    Current Research and Scholarly InterestsMultimodality treatment of rectal cancer
    Sphincter preserving procedures for rectal cancer
    Laparoscopic colon and rectal surgery
    Surgical education

  • Jeanne Shen

    Jeanne Shen

    Associate Professor of Pathology

    Current Research and Scholarly InterestsGastrointestinal and pancreatobiliary pathology, with major emphasis on GI and pancreatic neoplasia, inflammatory bowel disease, biodesign innovation, and the application of machine learning to digital pathology.

  • Gavin Sherlock

    Gavin Sherlock

    Professor of Genetics

    Current Research and Scholarly InterestsEvolution and the adaptive landscape using yeast as a model; Defining yeast transcriptomes; chromosomal evolution in hybrid yeast species

  • Judith Shizuru

    Judith Shizuru

    Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)

    Current Research and Scholarly InterestsTransplantation of defined populations of allogeneic hematopoietic cells. Specifically, the way in which hematopoietic cell grafts alter antigen specific immune responses to allo-, auto- and viral antigens. The cellular and molecular basis of resistance to engraftment of allogeneic hematopoietic stem cells.

  • Linda M. Dairiki Shortliffe

    Linda M. Dairiki Shortliffe

    Stanley McCormick Memorial Professor in the School of Medicine, Emerita

    Current Research and Scholarly InterestsThe timing for intervention in obstruction in the infant and child is poorly understood.Our group has been interested in trying to define the risks that may be involved in obstructive and infectious uropathies and discovering early signs of damage to the urinary tract and kidney. We have explored ways of imaging the urinary tract using nonionizing radiation (US, MRI). We have studied the relationships of sex steroid hormones, pregnancy, reflux, urinary tract infection and urinary tract function.

  • Joseph Shrager

    Joseph Shrager

    Professor of Cardiothoracic Surgery

    Current Research and Scholarly InterestsIn clinical research, Dr. Shrager studies outcomes in a variety of areas within Thoracic Surgery including: parenchyma-sparing operations and minimally invasive resections for lung cancer, transcervical thymectomy for myasthenia gravis, diaphragm plication, and surgical treatment of emphysema.

    Dr. Shrager's lab is focused on the impact of disease states upon the diaphragm. His group published the seminal paper (NEJM) describing diaphragm atrophy assoc'd with mechanical ventilation.

  • Surbhi Sidana, MD

    Surbhi Sidana, MD

    Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Sidana is a hematologist/oncologist who is fellowship trained in advanced hematology with an emphasis on myeloma, amyloidosis, and dysproteinemia disorders. She is an Assistant Professor in the Department of Medicine, Division of Blood and Marrow Transplantation & Cellular Therapy, at Stanford University School of Medicine. She leads the Myeloma Cellular Immunotherapy program at Stanford.

    Her areas of expertise include transplantation and novel cellular immunotherapies such as CAR-T-cell therapy for patients with multiple myeloma. For each patient, Dr. Sidana develops a personalized care plan designed to optimize outcomes and quality of life.

    Dr. Sidana conducts extensive research. Currently, she is conducting clinical trials of CAR-T therapy and bispecific T-cell engagers for treatment of patients with myeloma. She is studying patients’ access to CAR-T cell therapy, the financial burden of the treatment, and its impact on patients’ quality of life and cognitive function.

    Dr Sidana has received a grant from the Stanford Medicine Cancer Institute and NIH funding through the Stanford KL2 program to study adverse events of CAR-T therapy on patients and monitoring of patients undergoing CAR-T therapy using wearable devices.

    In the past, Dr. Sidana received Conquer Cancer Foundation Young Investigator Award from the American Society of Clinical Oncology for her research on the impact of clinical trial participation on patients with multiple myeloma and lymphoma. She has also received grants from the Amyloidosis Foundation and International Waldenstrom’s Macrogloulinemia Foundation to understand AL amyloidosis, a rare disease caused by buildup of an abnormal protein.

    Dr. Sidana has given presentations at regional and national conferences and her work has been published in high-impact journals.

    Dr. Sidana has been recognized for her work with many honors, including an Outstanding Hematology/Oncology Fellow award and Outstanding Research Fellow award from the Mayo Clinic.

    She is a member of the American Society of Hematology, American Society of Clinical Oncology, International Myeloma Society, International Society of Amyloidosis, and American Society of Transplantation & Cellular Therapy. Dr. Sidana is often an invited speaker at patient support groups as well as symposia and workshops for her peers.

  • Arend Sidow

    Arend Sidow

    Professor of Pathology and of Genetics
    On Leave from 04/01/2024 To 02/21/2025

    Current Research and Scholarly InterestsWe have a highly collaborative research program in the evolutionary genomics of cancer. We apply well-established principles of phylogenetics to cancer evolution on the basis of whole genome sequencing and functional genomics data of multiple tumor samples from the same patient. Introductions to our work and the concepts we apply are best found in the Newburger et al paper in Genome Research and the Sidow and Spies review in TIGS.

    More information can be found here: http://www.sidowlab.org

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers

  • Bob Sinclair

    Bob Sinclair

    Charles M. Pigott Professor in the School of Engineering

    BioUsing high-resolution transmission electron microscopy, Sinclair studies microelectronic and magnetic thin film microstructure.

  • Eila C. Skinner

    Eila C. Skinner

    Thomas A. Stamey Research Professor of Urology

    Current Research and Scholarly InterestsMy research focuses on outcomes in the treatment of muscle invasive and high-grade non-muscle invasive bladder cancer. This includes identifying markers of prognosis, predictive markers for response to surgery and chemotherapy, and working toward an individualized, multidisciplinary approach to disease management. I have also focused on optimizing the use of lower urinary tract reconstruction in patients undergoing cystectomy, and developing interventions to improve patient quality of life.

  • Stephen Skirboll

    Stephen Skirboll

    Associate Professor of Neurosurgery

    Current Research and Scholarly InterestsMy research focuses on screening strategies to identify and characterize cancer stem cells (CSCs) in human gliomas. We are pursuing this in several ways: 1) a novel colony-forming antibody live cell array to identify distinct CSC surface phenotypes, 2) RNAi screens to identify kinases critical for CSC tumorigenicity, 3) high throughput small molecule and chemical screens to identify compounds that selectively kill or target CSCs, and 4) identifying CSCs using the tumor specific EGFRvIII

  • Jan Skotheim

    Jan Skotheim

    Professor of Biology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsMy overarching goal is to understand how cell growth triggers cell division. Linking growth to division is important because it allows cells to maintain specific size range to best perform their physiological functions. For example, red blood cells must be small enough to flow through small capillaries, whereas macrophages must be large enough to engulf pathogens. In addition to being important for normal cell and tissue physiology, the link between growth and division is misregulated in cancer.

  • Melody Smith, MD, MS

    Melody Smith, MD, MS

    Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

    BioDr. Smith is a board-certified, fellowship-trained medical oncologist and hematologist. She is an assistant professor in the Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.

    She is a physician-scientist who conducts extensive research. She completed a fellowship at the National Institutes of Health (NIH) in the Clinical Research Training (now, the Medical Research Scholars) Program and she was a post-doctoral researcher at Memorial Sloan Kettering Cancer Center. Her research focuses on studies evaluating strategies whereby donor T cells can be administered to improve outcomes following blood and marrow transplant. Specifically, she studies novel treatment strategies using chimeric antigen receptor (CAR) T cell therapy.

    Dr. Smith has been invited to present the findings of her research at regional, national, and international conferences. At the Insights in Hematology Conference, she focused on the use of CAR T cells for blood cancers, whereas she presented her investigations on the associations between CAR T cells and the intestinal microbiome at the European Society for Blood and Marrow Transplantation. Further, at the annual meeting of the American Society of Gene & Cell Therapy, she addressed the importance of training scientists from underrepresented populations.

    Dr. Smith has co-authored articles on topics within the field of cancer immunology, including cancer immunotherapy, stem cell transplantation, and CAR T cell therapy. Her work has appeared in journals, including Biology of Blood and Marrow Transplantation, Blood Advances, Leukemia, Nature, Nature Immunology, Nature Medicine, and elsewhere.

    She serves a peer reviewer for publications in various journals, such as Biology of Blood and Marrow Transplantation, Haematologica, and ImmunoMedicine. She also has co-written chapters in books, including Pocket Oncology, Current Concepts and Controversies in Hematopoietic Cell Transplantation, and Advanced Concepts in Human Immunology: Prospects for Disease Control.

    Dr. Smith has also earned numerous honors. The American Society of Hematology, Society for Immunotherapy of Cancer, European Society for Blood and Marrow Transplantation, and many other professional societies and organizations have recognized her achievements as a clinician, researcher, and scholar.

    She is a member of the American Society of Hematology (ASH) Subcommittee on Immunotherapy and the co-chair of the Committee on Trainees and Junior Faculty for the American Society of Transplantation and Cellular Therapy (ASTCT). Other positions in service to professional organizations include co-chairing committees and task forces dedicated to promoting diversity among hematology and cell therapy specialists.

  • Michael Snyder, Ph.D.

    Michael Snyder, Ph.D.

    Stanford W. Ascherman Professor of Genetics

    Current Research and Scholarly InterestsOur laboratory use different omics approaches to study a) regulatory networks, b) intra- and inter-species variation which differs primarily at the level of regulatory information c) human health and disease. For the later we have established integrated Personal Omics Profiling (iPOP), an analysis that combines longitudinal analyses of genomic, transcriptomic, proteomic, metabolomic, DNA methylation, microbiome and autoantibody profiles to monitor healthy and disease states